PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
2024-2 NIH/CDC small business grant invites US firms to propose innovative solutions related to NIH/CDC research missions, requiring 1 clinical trial.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: September 5, 2024 | January 5, 2025 | April 5, 2025 | September 5, 2025
Funding Amounts: Phase I: up to $306,872 (6 months) | Phase II: up to $2,045,816 (2 years); higher budgets possible for select topics
Summary: Supports U.S. small businesses to conduct innovative R&D aligned with NIH/CDC missions, requiring at least one clinical trial per application.
Key Information: Only applications proposing clinical trials are eligible; strict eligibility and disclosure requirements apply.
Description
This opportunity invites U.S. small businesses to apply for Small Business Innovation Research (SBIR) grants to develop and commercialize innovative technologies or products that address the research and development missions of the National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). All applications must propose at least one clinical trial. Projects should align with the scientific priorities of one or more participating NIH Institutes or CDC Centers.
The SBIR program is designed to stimulate technological innovation, strengthen the role of small businesses in federal R&D, and increase commercialization of innovations. This solicitation supports Phase I (feasibility), Phase II (development), Fast-Track (combined Phase I/II), Direct-to-Phase II (NIH only), and Phase IIB (additional development) applications.
